logo
episode-header-image
Jul 2023
20m 4s

Anglerfish, Gila Monsters, and the Origi...

The Motley Fool
About this episode

Weight loss drug sales are estimated to hit $44 billion by 2030. Many of these treatments can thank previously obscure research on a carnivorous deep sea fish for their development. Rolfe Winkler is a reporter for the Wall Street Journal covering digital health. Ricky Mulvey caught up with Winkler to discuss: - The origins and science behind weight loss drugs. - The challenge of selling lizard venom research to pharmaceutical companies. - What decades-old research on anglerfish reveals about modern side effects for Ozempic. - And why it’s “not too hard” to keep dozens of Gila Monsters in your basement. “Monster Diet Drugs Like Ozempic Started With Actual Monsters”: https://www.wsj.com/articles/ozempic-mounjaro-gila-monster-anglerfish-8c9c1ff2 Companies mentioned: NVO, LLY Host: Ricky Mulvey Guest: Rolfe Winkler Engineers: Tim Sparks, Heather Horton

Learn more about your ad choices. Visit megaphone.fm/adchoices

Up next
Yesterday
AI, Superman, and Solar’s Kryptonite
Oh yes, we’re talking all kinds of stocks! (00:21) Jason Hall and Matt Frankel discuss: - AI stocks in the data center space (including CoreWeave) - Winners and losers in energy and solar from the Big Beautiful Bill. - With Superman coming out, we rank the intellectual property o ... Show More
42m 1s
Jul 10
Taiwan Semi’s $100 billion plan and housing is hot!
Taiwan Semiconductor’s earnings beat Wall Street expectations, the housing market is picking up steam after, and TopBuild & Ferrero International go shopping. Tyler Crowe and Matt Frankel discuss: - Taiwan Semiconductor’s most recent earnings report - The torrid pace of AI spendi ... Show More
22m 6s
Jul 9
Starbucks' China Challenge and Decoding Meta's AI Push
Starbucks is looking to sell a stake in its China business, Hershey has a new CEO and Meta hits the gas on AI. Jason Moser and Lou Whiteman discuss: - Starbucks' move to sell part of its China business. - Hershey hires a new CEO. - Meta moves for more talent and invests in eyewea ... Show More
20m 38s
Recommended Episodes
Jun 2024
The weight-loss drug revolution
Diabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of ... Show More
17m 28s
Jul 2023
How Drugs Like Ozempic Are Changing What We Think About Weight Loss
You may have heard about Ozempic, Wegovy and Mounjaro. It’s tough to miss the online chatter, the ads on TV and all the news coverage. They are part of a class of drugs originally designed to treat diabetes, and all three have been shown to help people lose significant amounts of ... Show More
30m 50s
Feb 2024
The Big Business Behind Weight Loss Drugs
It’s become a multibillion-dollar business: weight loss drugs. Demand is high, as is the cost. How did medications like Ozempic, Wegovy, Mounjaro and Zepbound become so popular and so profitable? And what kind of impact might they have on the future of food and healthcare? Dr. Sa ... Show More
33m 54s
Mar 2017
113. Susan Peirce Thompson went from being addicted to drugs and alcohol to turning her life around, and building a multi-million dollar weight loss business.
Susan Peirce Thompson is an entrepreneur, brain and cognitive scientist, and food psychologist. She's a Ph.D, and author of the new book Bright Line Eating: The Science of Living Happy, Thin, & Free. She built her business to over $6MM in revenue (with a 300k+ list) in under a ye ... Show More
30m 9s
Mar 2024
The Scientific Journey Behind Ozempic (with Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor)
On our Novo Nordisk episode, we covered the business of Ozempic, the GLP-1 taking the world by storm. On this episode, we dive into the science of the molecule semaglutide (and its predecessor liraglutide) with the world expert on the topic, Lotte Bjerre Knudsen. Lotte is Novo No ... Show More
1 h
Nov 2023
#705: Dr. Willoughby Britton — The Hidden Risks of Meditation, Overlaps with Psychedelic Risks, Harm Reduction Strategies, How to Choose a Retreat, Near-Death Experiences, and More
Brought to you by Momentous high-quality supplements, Nordic Naturals Ultimate Omega fish oil, and Eight Sleep’s Pod Cover sleeping solution for dynamic cooling and heating.Willoughby Britton, PhD is a clinical psychologist, an associate professor of psychiatry and human behavior ... Show More
2h 3m
Mar 2023
NHS weight-loss drug
James Gallagher asks whether a weight-loss drug on the NHS heralds a new era in tackling obesity? He meets Jan who lost nearly 4 stone after being part of a trial taking a weekly injection of Semaglutide for 15 months alongside advice on meals and exercise. However, when people s ... Show More
27m 57s
Jan 2023
Terence Flynn: The Next Blockbuster for Pharma?
As new weight management medications are being developed, might the obesity market parallel the likes of hypertension or high blood pressure to become the next blockbuster Pharma category? ----- Transcript ----- Welcome to Thoughts on the Market. I'm Terence Flynn, Head of the U. ... Show More
3m 12s
Oct 2023
Confronting An Obesity Doctor About Ozempic & Weight Loss | Dr. Rocio Salas-Whalen
Watch the full video interview here: https://go.doctormikemedia.com/youtube/RSWOzempic Dr. Rocio Salas-Whalen is a double board-certified physician with broad experience across all facets of endocrinology, with a particular emphasis on obesity, diabetes and thyroid disorders. She ... Show More
52m 37s